Citigroup Maintains Buy on Medline, Lowers Price Target to $55

Benzinga Newsdesk www.benzinga.com Negative 63.2%

Neg 63.2% Neu 0% Pos 0%

Citigroup analyst Patrick Donnelly maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $60 to $55.